vs
ICU MEDICAL INC（ICUI）与iRhythm Holdings, Inc.（IRTC）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是iRhythm Holdings, Inc.的2.6倍（$540.7M vs $208.9M）。iRhythm Holdings, Inc.净利率更高（2.7% vs -2.9%，领先5.6%）。iRhythm Holdings, Inc.同比增速更快（27.1% vs -14.1%）。ICU MEDICAL INC自由现金流更多（$36.0M vs $14.5M）。过去两年iRhythm Holdings, Inc.的营收复合增速更高（25.8% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
iRhythm Holdings是一家专注于心脏护理领域的数字医疗企业，开发可穿戴动态心脏监测设备及配套AI分析工具，主要服务美国市场的医疗机构与患者，帮助检测房颤等心律异常病症，为临床诊断提供可靠的数据支持。
ICUI vs IRTC — 直观对比
营收规模更大
ICUI
是对方的2.6倍
$208.9M
营收增速更快
IRTC
高出41.3%
-14.1%
净利率更高
IRTC
高出5.6%
-2.9%
自由现金流更多
ICUI
多$21.5M
$14.5M
两年增速更快
IRTC
近两年复合增速
-2.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $208.9M |
| 净利润 | $-15.7M | $5.6M |
| 毛利率 | 37.5% | 70.9% |
| 营业利润率 | 1.0% | 1.1% |
| 净利率 | -2.9% | 2.7% |
| 营收同比 | -14.1% | 27.1% |
| 净利润同比 | 34.0% | 518.5% |
| 每股收益（稀释后） | $-0.63 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIIRTC
| Q4 25 | $540.7M | $208.9M | ||
| Q3 25 | $537.0M | $192.9M | ||
| Q2 25 | $548.9M | $186.7M | ||
| Q1 25 | $604.7M | $158.7M | ||
| Q4 24 | $629.8M | $164.3M | ||
| Q3 24 | $589.1M | $147.5M | ||
| Q2 24 | $596.5M | $148.0M | ||
| Q1 24 | $566.7M | $131.9M |
净利润ICUIIRTC
| Q4 25 | $-15.7M | $5.6M | ||
| Q3 25 | $-3.4M | $-5.2M | ||
| Q2 25 | $35.3M | $-14.2M | ||
| Q1 25 | $-15.5M | $-30.7M | ||
| Q4 24 | $-23.8M | $-1.3M | ||
| Q3 24 | $-33.0M | $-46.2M | ||
| Q2 24 | $-21.4M | $-20.1M | ||
| Q1 24 | $-39.5M | $-45.7M |
毛利率ICUIIRTC
| Q4 25 | 37.5% | 70.9% | ||
| Q3 25 | 37.4% | 71.1% | ||
| Q2 25 | 37.9% | 71.2% | ||
| Q1 25 | 34.7% | 68.8% | ||
| Q4 24 | 36.1% | 70.0% | ||
| Q3 24 | 34.8% | 68.8% | ||
| Q2 24 | 34.8% | 69.9% | ||
| Q1 24 | 32.7% | 66.3% |
营业利润率ICUIIRTC
| Q4 25 | 1.0% | 1.1% | ||
| Q3 25 | 2.6% | -4.4% | ||
| Q2 25 | 1.9% | -10.0% | ||
| Q1 25 | 2.1% | -20.5% | ||
| Q4 24 | 6.0% | -2.5% | ||
| Q3 24 | 1.4% | -34.1% | ||
| Q2 24 | 1.3% | -15.5% | ||
| Q1 24 | -1.9% | -28.9% |
净利率ICUIIRTC
| Q4 25 | -2.9% | 2.7% | ||
| Q3 25 | -0.6% | -2.7% | ||
| Q2 25 | 6.4% | -7.6% | ||
| Q1 25 | -2.6% | -19.3% | ||
| Q4 24 | -3.8% | -0.8% | ||
| Q3 24 | -5.6% | -31.3% | ||
| Q2 24 | -3.6% | -13.6% | ||
| Q1 24 | -7.0% | -34.6% |
每股收益（稀释后）ICUIIRTC
| Q4 25 | $-0.63 | $0.18 | ||
| Q3 25 | $-0.14 | $-0.16 | ||
| Q2 25 | $1.43 | $-0.44 | ||
| Q1 25 | $-0.63 | $-0.97 | ||
| Q4 24 | $-0.97 | $-0.03 | ||
| Q3 24 | $-1.35 | $-1.48 | ||
| Q2 24 | $-0.88 | $-0.65 | ||
| Q1 24 | $-1.63 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $583.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $152.7M |
| 总资产 | $4.1B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIIRTC
| Q4 25 | — | $583.8M | ||
| Q3 25 | — | $565.2M | ||
| Q2 25 | — | $545.5M | ||
| Q1 25 | — | $520.6M | ||
| Q4 24 | $308.6M | $535.6M | ||
| Q3 24 | $312.5M | $522.0M | ||
| Q2 24 | $302.6M | $561.5M | ||
| Q1 24 | $251.4M | $569.1M |
股东权益ICUIIRTC
| Q4 25 | $2.1B | $152.7M | ||
| Q3 25 | $2.1B | $121.9M | ||
| Q2 25 | $2.1B | $103.7M | ||
| Q1 25 | $2.0B | $86.7M | ||
| Q4 24 | $2.0B | $90.9M | ||
| Q3 24 | $2.0B | $71.8M | ||
| Q2 24 | $2.0B | $99.2M | ||
| Q1 24 | $2.1B | $90.3M |
总资产ICUIIRTC
| Q4 25 | $4.1B | $1.0B | ||
| Q3 25 | $4.1B | $995.2M | ||
| Q2 25 | $4.1B | $964.0M | ||
| Q1 25 | $4.2B | $926.1M | ||
| Q4 24 | $4.2B | $931.4M | ||
| Q3 24 | $4.3B | $909.7M | ||
| Q2 24 | $4.3B | $919.2M | ||
| Q1 24 | $4.3B | $909.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $14.5M |
| 自由现金流率自由现金流/营收 | 6.6% | 6.9% |
| 资本支出强度资本支出/营收 | 4.6% | 5.6% |
| 现金转化率经营现金流/净利润 | — | 4.70× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $34.5M |
8季度趋势，按日历期对齐
经营现金流ICUIIRTC
| Q4 25 | $60.6M | $26.2M | ||
| Q3 25 | $56.7M | $34.9M | ||
| Q2 25 | $11.2M | $27.7M | ||
| Q1 25 | $51.3M | $-7.9M | ||
| Q4 24 | $40.2M | $19.2M | ||
| Q3 24 | $36.1M | $24.3M | ||
| Q2 24 | $82.0M | $11.8M | ||
| Q1 24 | $45.8M | $-52.0M |
自由现金流ICUIIRTC
| Q4 25 | $36.0M | $14.5M | ||
| Q3 25 | $27.6M | $20.1M | ||
| Q2 25 | $-8.5M | $17.3M | ||
| Q1 25 | $36.7M | $-17.3M | ||
| Q4 24 | $16.1M | $12.4M | ||
| Q3 24 | $16.2M | $15.5M | ||
| Q2 24 | $62.5M | $3.4M | ||
| Q1 24 | $29.9M | $-61.8M |
自由现金流率ICUIIRTC
| Q4 25 | 6.6% | 6.9% | ||
| Q3 25 | 5.1% | 10.4% | ||
| Q2 25 | -1.5% | 9.3% | ||
| Q1 25 | 6.1% | -10.9% | ||
| Q4 24 | 2.6% | 7.5% | ||
| Q3 24 | 2.7% | 10.5% | ||
| Q2 24 | 10.5% | 2.3% | ||
| Q1 24 | 5.3% | -46.8% |
资本支出强度ICUIIRTC
| Q4 25 | 4.6% | 5.6% | ||
| Q3 25 | 5.4% | 7.7% | ||
| Q2 25 | 3.6% | 5.6% | ||
| Q1 25 | 2.4% | 5.9% | ||
| Q4 24 | 3.8% | 4.2% | ||
| Q3 24 | 3.4% | 6.0% | ||
| Q2 24 | 3.3% | 5.7% | ||
| Q1 24 | 2.8% | 7.4% |
现金转化率ICUIIRTC
| Q4 25 | — | 4.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
